Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tecan Genomics Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners but are contained within 1 distinct art unit. ZHANG, KAIJIANG is noted as the busiest examiner, holding 1 pending office action.
While the portfolio involves 2 distinct examiners, the fact that they both operate within 1 distinct art unit suggests a consistent technological focus for these filings. The workload is split, as the busiest examiner holds 1 pending office action out of the 2 total. This distribution allows for variety in examiner perspective while maintaining a stable environment within 1 art unit, which may lead to more predictable prosecution outcomes compared to portfolios spread across multiple units. Practitioners can compare the responses from the 2 distinct examiners to identify common themes or differing interpretations within the same art unit. This internal comparison provides a dataset for refining the company's approach to patenting in this specific technology area. The presence of 2 pending office actions indicates a moderate level of active engagement with the patent office at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG, KAIJIANG | 1 | 77.2% | +34.3% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18341436 | COMPOSITIONS AND METHODS FOR IDENTIFICATION OF A DUPLICATE SEQUENCING READ | PHAM, KHAI QUYNH TIEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18218353 | REPURPOSING BEADS IN SAMPLE CLEANUP | ZHANG, KAIJIANG | — |
| Art Unit | Apps |
|---|---|
| 1684 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18218353 | REPURPOSING BEADS IN SAMPLE CLEANUP | ZHANG, KAIJIANG | 1684 | §102Other | Non-Final OA | — | Pending | Jul 05, 2023 |
| 18341436 | COMPOSITIONS AND METHODS FOR IDENTIFICATION OF A DUPLICATE SEQUENCING READ | PHAM, KHAI QUYNH TIEN | 1684 | §102§103§112DP | Final Rejection | — | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTecan Genomics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Kaijiang Zhang has the most, with 1 of Tecan Genomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
